Lihua Zhu to Carcinoma, Pancreatic Ductal
This is a "connection" page, showing publications Lihua Zhu has written about Carcinoma, Pancreatic Ductal.
Connection Strength
0.836
-
Parikh CN, DeMarco KD, Bhalerao N, Giwa HK, Kane GI, Dinnell RW, Ma B, Mori H, Brassil ML, Murphy KC, Zhao Z, Johnson C, Ramani S, Zhou L, Chibaya L, Qiao Y, Hu K, Zhu LJ, Lewis BC, Xue W, Pitarresi JR, Atukorale PU, Ruscetti M. Multiplexed cytokine and antigen mRNA administration generates durable anti-tumor immunity against pancreatic cancer. Nat Commun. 2026 Jun 19; 17(1).
Score: 0.215
-
Chibaya L, DeMarco KD, Lusi CF, Kane GI, Brassil ML, Parikh CN, Murphy KC, Chowdhury SR, Li J, Ma B, Naylor TE, Cerrutti J, Mori H, Diaz-Infante M, Peura J, Pitarresi JR, Zhu LJ, Fitzgerald KA, Atukorale PU, Ruscetti M. Nanoparticle delivery of innate immune agonists combined with senescence-inducing agents promotes T cell control of pancreatic cancer. Sci Transl Med. 2024 08 28; 16(762):eadj9366.
Score: 0.189
-
Malvi P, Chava S, Cai G, Hu K, Zhu LJ, Edwards YJK, Green MR, Gupta R, Wajapeyee N. HOXC6 drives a therapeutically targetable pancreatic cancer growth and metastasis pathway by regulating MSK1 and PPP2R2B. Cell Rep Med. 2023 11 21; 4(11):101285.
Score: 0.179
-
Chibaya L, Murphy KC, DeMarco KD, Gopalan S, Liu H, Parikh CN, Lopez-Diaz Y, Faulkner M, Li J, Morris JP, Ho YJ, Chana SK, Simon J, Luan W, Kulick A, de Stanchina E, Simin K, Zhu LJ, Fazzio TG, Lowe SW, Ruscetti M. EZH2 inhibition remodels the inflammatory senescence-associated secretory phenotype to potentiate pancreatic cancer immune surveillance. Nat Cancer. 2023 06; 4(6):872-892.
Score: 0.173
-
Rajurkar M, De Jesus-Monge WE, Driscoll DR, Appleman VA, Huang H, Cotton JL, Klimstra DS, Zhu LJ, Simin K, Xu L, McMahon AP, Lewis BC, Mao J. The activity of Gli transcription factors is essential for Kras-induced pancreatic tumorigenesis. Proc Natl Acad Sci U S A. 2012 Apr 24; 109(17):E1038-47.
Score: 0.080